TransCode Therapeutics (RNAZ) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free RNAZ Stock Alerts $1.16 +0.35 (+43.21%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHead to Head Review: TransCode Therapeutics (NASDAQ:RNAZ) and Tyra Biosciences (NASDAQ:TYRA)americanbankingnews.com - May 3 at 4:36 AMFDA clears TransCode's drug trial for advanced tumorsuk.investing.com - April 17 at 8:48 AMTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumorsglobenewswire.com - April 15 at 9:00 AMPromising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeuticsmarkets.businessinsider.com - April 4 at 2:37 AMTransCode Therapeutics Reports 2023 Results; Provides Business Updateglobenewswire.com - April 3 at 9:10 AMTransCode Therapeutics appoints new Chief Medical Officeruk.investing.com - March 30 at 4:57 PMTransCode Appoints Daniel Vlock As CMOmarkets.businessinsider.com - March 29 at 2:19 AMTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officerfinanznachrichten.de - March 28 at 11:16 AMTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officerglobenewswire.com - March 28 at 8:30 AMTransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatmentfinanznachrichten.de - March 11 at 2:00 PMTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatmentglobenewswire.com - March 11 at 9:00 AMTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congressglobenewswire.com - March 6 at 4:15 PMTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeuticfinance.yahoo.com - February 20 at 12:42 PMTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeuticglobenewswire.com - February 20 at 8:00 AMTranscode Therapeutics Inc (RNAZ)uk.investing.com - February 1 at 7:57 AMNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Marketfinance.yahoo.com - January 31 at 8:48 PMLooking Into TransCode Therapeutics's Recent Short Interestbenzinga.com - January 30 at 7:38 AMTransCode Collaborates With Debiopharm; Financial Terms Not Disclosedmarkets.businessinsider.com - January 29 at 12:45 PMTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancerfinance.yahoo.com - January 29 at 12:45 PMTransCode Therapeutics Announces Closing of $7.25 Million Public Offeringfinance.yahoo.com - January 22 at 6:20 PMWhy TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionmsn.com - January 19 at 2:23 PMTransCode Therapeutics Shares Slide to 52-Week Low on Planned Public Offeringmarketwatch.com - January 18 at 4:03 PMTransCode Therapeutics Announces Pricing of $7.25 Million Public Offeringfinance.yahoo.com - January 18 at 4:03 PMmarketbeat.com - January 18 at 1:31 PMTransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-40 Reverse Stock Splitfinanznachrichten.de - January 15 at 11:43 PMmarketbeat.com - January 15 at 6:07 AMTransCode Therapeutics Stock (NASDAQ:RNAZ) Dividends: History, Yield and Datesbenzinga.com - January 14 at 8:56 AMStocks to Watch: TransCode Therapeutics, Rackspace Technology, Williams-Sonomamarketwatch.com - January 12 at 7:52 PMTransCode Therapeutics announces retirement of CEOmsn.com - January 12 at 7:52 PMTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEOfinance.yahoo.com - January 12 at 7:52 PMTransCode Therapeutics Announces 1-for-40 Reverse Stock Splitfinance.yahoo.com - January 11 at 12:11 PMTransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectivesfinance.yahoo.com - January 4 at 10:16 AMTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138finance.yahoo.com - December 12 at 8:58 AMTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rulesfinance.yahoo.com - December 4 at 7:10 PMTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Updatefinance.yahoo.com - November 14 at 7:26 PMTransCode Therapeutics, Inc.: TransCode Therapeutics Withdraws Public Offeringfinanznachrichten.de - October 31 at 8:43 AMTransCode Therapeutics Withdraws Public Offeringfinance.yahoo.com - October 30 at 7:00 PMNasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditionsfinance.yahoo.com - October 27 at 12:00 PMWhy Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?investorplace.com - October 27 at 9:12 AMTransCode Therapeutics Announces Public Offering of Common Stockbenzinga.com - October 26 at 8:13 PMTransCode Therapeutics Announces Public Offering of Common Stockfinance.yahoo.com - October 26 at 8:13 PMTransCode Therapeutics Stock (NASDAQ:RNAZ), Analyst Ratings, Price Targets, Predictionsbenzinga.com - October 26 at 3:10 PMTransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138finance.yahoo.com - October 26 at 8:22 AMPromising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily Bodnarmarkets.businessinsider.com - October 25 at 2:45 PMTransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGAfinance.yahoo.com - October 16 at 12:37 PMTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Closing of $8.5 Million Public Offeringfinanznachrichten.de - September 30 at 12:13 AMTransCode Therapeutics Announces Closing of $8.5 Million Public Offeringfinance.yahoo.com - September 28 at 6:53 PMWhy Transcode Therapeutics (RNAZ) Stock Is Down Nearly 70%benzinga.com - September 26 at 2:06 PMTranscode Therapeutics stock whipsaws lower after cut price placingproactiveinvestors.com - September 26 at 9:06 AMWhy Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?msn.com - September 26 at 9:06 AM Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide RNAZ Media Mentions By Week RNAZ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAZ News Sentiment▼0.000.38▲Average Medical News Sentiment RNAZ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAZ Articles This Week▼11▲RNAZ Articles Average Week Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Atreca News Today Revelation Biosciences News Today Seelos Therapeutics News Today GeoVax Labs News Today Phio Pharmaceuticals News Today Virpax Pharmaceuticals News Today Evoke Pharma News Today Agile Therapeutics News Today ZyVersa Therapeutics News Today Soligenix News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAZ) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.